Developer of drugs for cholesterol-related diseases. The company focuses on the development of drugs for the treatment of refractory hypercholesterolemia, hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases by decreasing arterial cholesterol content and inflammation. The company's technology is based upon a platform of chimeric peptide mimetics of apolipoprotein E, a critical protein that directs cholesterol and triglyceride-rich lipoproteins to receptors on the liver.